Suppliers / Caplin Steriles

Caplin Steriles

India 62 employees 2 duplicate records merged Updated 9 July 2026

Caplin Steriles is a finished-dose manufacturer based in India. It appears in 52 regulatory filings across 3 regulators, without an active US DMF or CEP on file. Its filings concentrate with US FDA, COFEPRIS (MX) and MINSA (CR). Its GMP standing is certified by CDSCO (India), ANVISA (Brazil) and US FDA, among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 9 August 2024 as NAI. Customs aggregates show $5.0M of exports covering 102 molecules to 5 destinations in 2025.

0
active US DMFs
0
valid CEPs
3
registered plants 1 with an FDA FEI number
52
filings across 3 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 9 August 2024 NAI US FDA
  • 31 May 2023 VAI US FDA
  • 14 June 2019 VAI US FDA
  • 6 September 2018 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Gummidipoondi, United Arab Emirates Not on file
Gummidipoondi, India 3005035920
THIRUVALLUR, India Not on file

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA 40 1
COFEPRIS (MX) 7 None
MINSA (CR) 5 None
CDSCO (India) None 2
ANVISA (Brazil) None 2
EMA None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $2.7M 7
2025 Not reported $5.0M 5
2024 Not reported $20 1
2023 Not reported $320K 1

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Caplin Steriles comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 9 August 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts